EchoLaser is now NMPA approved

Elesta announces that the Chinese regulatory authority National Medical Products Administration (NMPA) has approved EchoLaser for use in prostatic diseases. This approval is a major achievement and represents a great opportunity for Elesta (distributed in China by Esaote). NMPA approval confirms once again the robustness of clinical data in urology, where EchoLaser has been demonstrated to be a safe and efficacious alternative to surgery for the treatment of Benign Prostatic Hyperplasia (BPH) and some forms of prostatic cancer.